Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
55 Results for "
time-dependent manner
" in MedChemExpress (MCE) Product Catalog:
Products (55)
55 Results for "time-dependent manner" in MCE Product Catalog:
22
22 Publications Verification
Synonyms: RP 35972; NSC 347901
Research Areas:
Oltipraz has an inhibitory effect on HIF-1α activation in a time-dependent manner, completely abrogating HIF-1α induction at ≥10 μM concentrations, the IC50 of Oltipraz for HIF-1α inhibition is 10 μM. Oltipraz is a potent Nrf2 activator.
10
Target:
Research Areas:
Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.
5
3
Category:
Plants Other Families Extract Menispermum dauricum Alkaloids Monophenols Menispermaceae Extract Phenols Disease Research Fields Isoquinoline Alkaloids Inflammation/Immunology Cancer
Target:
1
1 Cited Publications
Cat. No.: HY-N1410
CAS No.: 42206-94-0
1
1 Cited Publications
Target:
Research Areas:
GSK-J5 is a potent inhibitor of Schistosome and worm. GSK-J5 increases schistosomula mortality and adult worm motility and mortality, as well as egg oviposition, in a dose- and time-dependent manner .
Cat. No.: HY-P3579
CAS No.: 11063-17-5
Synonyms: GIP (1-42), porcine
Target:
Research Areas:
Cat. No.: HY-122653A
Purity: 98.02%
CCT367766 formic is a pirin PROTAC degrader. CCT367766 formic forms a ternary complex with cereblon and induces pirin depletion via the ubiquitin-proteasome pathway in a concentration- and time-dependent manner. CCT367766 formic can be used for ovarian cancer research .
Cat. No.: HY-133862
CAS No.: 70375-43-8
Research Areas:
SCH-202676 is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 has antiviral activity and inhibits 3CL pro in a time-dependent manner with an IC50 value of 0.655 µM .
Cat. No.: HY-P3089A
Target:
Research Areas:
Target:
Research Areas:
SCH-202676 hydrobromide is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 hydrobromide has antiviral activity and inhibits 3CL pro in a time-dependent manner with an IC50 value of 0.655 μM .
Cat. No.: HY-111560
CAS No.: 1956337-58-8
Target:
Research Areas:
IQM-266 is a Downstream Regulatory Element Antagonist Modulator (DREAM) ligand with a KD of 4.63 μM. IQM-266 inhibits the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner. IQM-266 also modulates A-type outward potassium currents (IA) from rat dorsal root ganglia (DRG) neurons. IQM-266 can be used for neurological disease research, such as Alzheimer’s disease and Huntington's disease (HD) .
Cat. No.: HY-151285
CAS No.: 2242031-31-6
Research Areas:
JAK-2-/3-IN-3 (compound ST4j) is a potent JAK2/3 inhibitor with IC50s of 13.00 and 14.86 nM for JAK2 and JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2 and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .
Cat. No.: HY-164895
CAS No.: 3080918-50-6
PIN1 degrader-1 is a covalent PIN1 degrader with an IC50 of 21.5 nM. PIN1 degrader-1 induces a decrease in the thermal stability of PIN1, and triggers PIN1 degradation in a concentration- and time-dependent manner across various cancer cells. PIN1 degrader-1 also reduces the viability of pancreatic cancer, breast cancer, prostate cancer and lung cancer cells. PIN1 degrader-1 can be used for research on pancreatic cancer, breast cancer, prostate cancer and non-small cell lung cancer .
Cat. No.: HY-174862
CAS No.: 3064086-31-0
Research Areas:
dASK1 is a PROTAC degrader of ASK1 that recruits cereblon. dASK1 promotes ASK1 degradation in a dose- and time-dependent manner via the ubiquitin-proteasome pathway. dASK1 can be used in studies of metabolic dysfunction-associated steatohepatitis .
Cat. No.: HY-164064
CAS No.: 2485052-87-5
Anticancer agent 230 (example 65) is a caseinolytic protease P (ClpP) activator with anticancer activity. Anticancer agent 230 is able to induce the degradation of mitochondrial proteins in SUM159 and MDA-MB-231 triple-negative breast cancer cells in a time-dependent manner .
Category:
Target:
Cat. No.: HY-N6842
CAS No.: 34532-67-7
Category:
Centipeda minima (L.) A. Braun & Asch. Infection Terpenoids Sesquiterpenes Plants Compositae Extract Disease Research Fields Cancer
Target:
Cat. No.: HY-173274
CAS No.: 3056259-55-0
Target:
Research Areas:
CB039 is a RBM39 molecular glue degrader with an IC50 of 36.7 nM against HCT-116 cells. CB039 induces RBM39 degradation in a dose- and time-dependent manner. This process depends on the Cullin-RING E3 ubiquitin ligase complex (CRL) and proteasome, and promotes the recruitment of RBM39 to the DCAF15-DDB1 complex with an IC50 of 594 nM. CB039 causes abnormal RNA splicing, reduces CEP192 protein levels, induces G2/M phase cell cycle arrest and mitotic spindle disorder. CB039 can be used in studies on RBM39-targeted protein degradation and colorectal cancer-related mechanisms .
Cat. No.: HY-P3089
CAS No.: 119128-61-9
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
